<DOC>
	<DOC>NCT01055652</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessment of AUC and Cmax of dapagliflozin</brief_summary>
	<brief_title>Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<criteria>Already on voglibose treatment with a steady dosage for at least 8 weeks Provision of informed consent prior to any study specific procedures Diagnosed with type 2 diabetes Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease. The investigator(s)judged that the Subject should not participate in the study according to screening test or medical history.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Japanese</keyword>
	<keyword>phase 1</keyword>
	<keyword>safety</keyword>
	<keyword>dapagliflozin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Drug-drug Interaction</keyword>
	<keyword>voglibose</keyword>
</DOC>